d694d329_GCP___Clinical_Trials_Registry__Safety_Issue
[Measure] PSA response rate and time-to-PSA-recurrence [Time Frame] 2 years [Safety Issue] 
Yes
N o
Y e s
A Neoadjuvant Immunologic Study of Androgen Deprivation Therapy Combined With a GM-CSF-secreting Allogeneic Prostate Cancer Vaccine and Low-dose Cyclophosphamide in Men With High-risk Localized Prostate Cancer Undergoing Radical Prostatectomy - ICH GCP - Clinical Trials Registry
Safety Issue